查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2002995

兽用疼痛管理市场：依动物种类、产品类型、给药途径、最终用户及通路划分－2026-2032年全球市场预测

Veterinary Pain Management Market by Animal Type, Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物疼痛管理市场价值将达到 22.5 亿美元，到 2026 年将成长到 24.5 亿美元，到 2032 年将达到 44.7 亿美元，年复合成长率为 10.28%。

主要市场统计数据
基准年 2025 22.5亿美元
预计年份：2026年 24.5亿美元
预测年份：2032年 44.7亿美元
复合年增长率 (%) 10.28%

一个全面的临床和商业性趋势框架，重新定义了动物疼痛管理的实践，无论物种或护理环境如何。

随着临床医生、生产商和经销商积极应对不断变化的动物健康重点、法律规范和客户期望，兽医疼痛管理领域正经历快速变革。药理学的进步、多方面镇痛的兴起以及人们对动物福利日益增长的关注，正在重塑伴侣动物、马匹和生产动物的治疗通讯协定。同时，科技驱动的诊断和数位治疗方法也开始影响疼痛的评估和管理方式，为整合到整个临床工作流程中创造了新的机会。

药理学、给药方法和分销管道的创新如何共同重塑兽医镇痛的临床通讯协定和商业策略？

在科学创新、监管改革和相关人员期望变化的推动下，兽医镇痛领域正经历着一场变革。非类固醇消炎剂的进步、局部麻醉剂製剂的改进以及对鸦片类药物合理使用的重新关注，正在改变临床实践中的治疗流程。同时，给药途径的进步，例如长效注射剂和经皮製剂，能够延长镇痛持续时间并遵守用药，尤其是在门诊和居家照护环境中。

评估美国在 2025 年宣布或实施的关税措施对供应链、采购和临床连续性的连锁影响。

美国计划于2025年加征关税，将对动物疼痛管理领域的相关人员产生多方面的影响，包括供应链、采购成本和策略采购决策。依赖全球生产网路采购活性成分、辅料或成品製剂的製造商可能面临更高的收货成本和更长的前置作业时间，迫使他们重新考虑供应商多元化和近岸外包方案。对于契约製造和经销商，进口关税的增加可能会压缩利润空间，促使他们提高营运效率并与分销通路合作伙伴重新谈判贸易条款。

各细分市场的策略挑战：动物类型、治疗领域、给药途径、最终用户和分销管道的选择如何影响临床引入和商业性定位。

透过市场区隔获得的洞见揭示了不同动物类型、产品类别、给药途径、最终用户和分销管道在临床和商业性行为方面的差异。按动物类型（猫、狗、马、牲畜）分析表明，由于物种特异性的动态、给药复杂性和客户期望，镇痛药的使用模式存在差异，从而推动了差异化的产品开发和标籤策略。产品类型细分揭示了局部麻醉剂、非类固醇消炎剂 ( NSAIDs) 和鸦片类药物之间的差异，导致监管审查等级、合理使用注意事项和临床适应症各不相同。 NSAIDs非类固醇消炎剂还可根据特定药物进一步细分，例如卡洛芬、氟尼辛、美洛昔康和罗贝考昔，每种药物都具有其独特的安全性特征和兽医製剂倾向。

美洲、欧洲、中东、非洲和亚太地区的法规、临床实践和分销方面的区域细微差别会影响准入和商业化策略。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势差异显着，每个地区都有独特的法规结构、临床实践模式和供应链结构，这些都会影响产品的取得和商业化。在美洲，虽然兽医院的整合和数位化采购的日益普及提高了效率，但人们对服务包装和培训支援的期望也越来越高。监管管道往往专注于已建立的药物安全监测系统，这些系统指南上市后监测策略。

製药公司和专业动物用药品公司之间的竞争和策略行动，透过专注于证据、服务和分销管道来实现差异化。

兽用疼痛管理领域的竞争格局呈现出多元化的特点，既有成熟的製药公司，也有专注于动物用药品研发的专业公司，还有不断开发新配方和给药系统的创新企业。主要企业优先考虑建立可靠的临床证据、进行针对兽医专业人士的精准宣传活动，并加大对产品安全监测的投入，以实现产品差异化。为了寻求配方科学、分销网络或区域监管方面的专业知识等互补能力，战略联盟和许可合作十分普遍。

为製造商和经销商提供切实可行的策略措施，以增强供应韧性，加快临床医生采用，并优化跨通路的商业性方法。

产业领导企业应推动一系列切实可行的倡议，以增强市场韧性，加速差异化治疗方法的推广应用，并使商业模式适应不断变化的临床环境。首先，製造商和经销商需要实施全面的价值链映射和双源采购策略，以减轻关税波动和原材料短缺的影响。其次，投资于兽医专业人员和饲主的多面向镇痛教育，将有助于循证处方笺，并透过改善可证实的治疗效果和提高遵守用药来提升产品价值。

采用严谨的混合方法研究途径，结合专家访谈、临床文献整合和基于情境的供应链分析，可以获得实用的见解。

本分析的调查方法结合了定性专家访谈、系统性文献综述以及监管指南和临床实践资源，以确保从所有相关人员的角度出发，获得平衡的观点。主要资讯来源包括与执业兽医、药理学家、监管专家和分销主管进行的结构化讨论，以了解实际决策因素、治疗偏好和采购实践。次要资讯来源包括同行评审的临床研究、药理学教科书和公开的监管文件，检验关键镇痛药及其给药途径的安全性、给药注意事项和标籤说明。

整合协调临床创新、监管期望和商业性韧性的策略重点，将改善动物疼痛管理和组织绩效。

总之，动物疼痛管理领域正处于一个转折点，临床创新、不断变化的经销管道和宏观经济压力相互交织，重新定义了机会和风险。积极整合供应链韧性、投资于临床医生教育并根据物种和环境特定需求量身定制产品和渠道策略的相关人员，将更有利于改善患者疗效并确保商业性竞争力。考虑到监管预期、给药途径偏好和终端用户采购行为之间的相互作用，需要製定一项协调一致的策略，将临床证据与切实可行的打入市场策略相结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：兽医疼痛管理市场：依动物类型划分

  • 猫
  • 狗
  • 马
  • 家畜

第九章：兽医疼痛管理市场：依产品类型划分

  • 局部麻醉剂
  • 非类固醇消炎剂
    • 卡洛芬
    • 氟尼辛
    • 美洛昔康
    • 罗贝那昔布
  • 阿片类药物

第十章：兽医疼痛管理市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服
  • 外用
    • 凝胶
    • 修补
    • 喷
  • 经皮

第十一章：兽医疼痛管理市场：依最终用户划分

  • 网路药房
  • 研究机构
  • 零售药房
  • 动物诊所
  • 动物医院

第十二章：兽医疼痛管理市场：依通路划分

  • 直销
  • 兽医院药房
  • 网路药房
  • 零售药房

第十三章 动物疼痛管理市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：兽医疼痛管理市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：兽医疼痛管理市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国兽医疼痛管理市场

第十七章：中国兽用疼痛管理市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-957C47F93EAD

The Veterinary Pain Management Market was valued at USD 2.25 billion in 2025 and is projected to grow to USD 2.45 billion in 2026, with a CAGR of 10.28%, reaching USD 4.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.25 billion
Estimated Year [2026] USD 2.45 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 10.28%

Comprehensive framing of clinical and commercial dynamics redefining veterinary pain management practices across species and care settings

The veterinary pain management landscape is undergoing rapid transformation as clinicians, manufacturers, and distributors respond to evolving animal health priorities, regulatory frameworks, and client expectations. Advances in pharmacology, a shift toward multimodal analgesia, and heightened attention to animal welfare are reshaping protocols across companion, equine, and production animal practice. At the same time, technology-enabled diagnostics and digital therapeutics are beginning to influence how pain is assessed and managed, creating new opportunities for integration across clinical workflows.

Decision-makers must understand not only product-level innovations but also changes in delivery modalities, administration preferences, and end-user procurement pathways. This report synthesizes clinical, commercial, and distributional dynamics to provide a consolidated view of current practice and emergent pressures. By focusing on treatment modalities, administration routes, and practitioner adoption behaviors, the analysis highlights actionable implications for product development, regulatory engagement, and commercial strategy. Transitional context links clinical need to market opportunity and frames the strategic considerations that follow.

How innovations in pharmacology, delivery methods, and distribution channels are jointly reshaping clinical protocols and commercial strategies in veterinary analgesia

The landscape for veterinary analgesia is experiencing transformative shifts driven by scientific innovation, regulatory recalibration, and changing stakeholder expectations. Advances in nonsteroidal anti-inflammatory agents, refinement of local anesthetic formulations, and renewed attention to opioid stewardship are altering therapeutic algorithms in clinical practice. Concurrently, progress in routes of administration-such as long-acting injectables and transdermal delivery systems-enables extended analgesic coverage and improved compliance, particularly in outpatient or home-care environments.

On the commercial side, distribution channels are fragmenting as digital pharmacies and direct-to-consumer models gain traction, prompting manufacturers to reassess channel strategies and patient support services. Veterinary clinics and hospitals are evolving into more sophisticated care hubs that demand integrated product support, training, and evidence-based protocols. These converging forces are incentivizing cross-disciplinary collaborations among pharmacologists, device developers, and veterinary practitioners to co-develop solutions that meet rising standards for efficacy, safety, and animal welfare, thereby reshaping competitive dynamics and go-to-market approaches.

Evaluating the cascading supply chain, procurement, and clinical continuity effects stemming from United States tariff measures announced or implemented in 2025

The prospect of tariffs introduced by the United States in 2025 carries multifaceted implications for veterinary pain management stakeholders, affecting supply chains, procurement costs, and strategic sourcing decisions. Manufacturers that rely on global manufacturing networks for active pharmaceutical ingredients, excipients, or finished formulations may face higher landed costs and disrupted lead times, prompting a reassessment of supplier diversification and nearshoring options. For contract manufacturers and distributors, greater import duties can compress margins and incentivize operational efficiencies or renegotiated commercial terms with channel partners.

Clinics and hospitals that procure proprietary or specialized formulations may experience procurement friction as distributors pass through cost increases or adjust inventory policies. In response, buyers could pursue longer-term purchase agreements, seek alternative generics, or increase onshore stockpiling to mitigate short-term volatility. Additionally, regulatory compliance, customs processing, and documentation burdens could introduce administrative overheads that slow product introductions. Collectively, these dynamics underscore the importance of scenario planning, supply chain mapping, and proactive engagement with logistics partners to preserve continuity of care and maintain access to critical analgesic therapies.

Segment-driven strategic imperatives showing how species, therapeutic class, administration route, end user, and distribution choices shape clinical adoption and commercial positioning

Insights derived from segmentation illuminate distinct clinical and commercial behaviors across animal type, product class, administration route, end user, and distribution pathways. When analyzed by animal type-cats, dogs, equine, and livestock-adoption patterns for analgesic classes diverge due to species-specific pharmacodynamics, dosing complexity, and client expectations, driving differentiated product development and labeling strategies. Within product type segmentation, distinctions among local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids reveal varying regulatory scrutiny, stewardship considerations, and clinical indications; the nonsteroidal anti-inflammatory category further differentiates around agents such as carprofen, flunixin, meloxicam, and robenacoxib, each associated with unique safety profiles and veterinary prescribing preferences.

Route of administration segmentation-injectable, oral, topical, and transdermal-highlights user-centric trade-offs between onset, duration, and ease of administration; injectable options subdivide into intramuscular, intravenous, and subcutaneous approaches tailored to care setting and patient tolerance, while topical applications encompass gels, patches, and sprays that support at-home management or localized therapy. End user segmentation captures how online pharmacies, research institutes, retail pharmacies, veterinary clinics, and veterinary hospitals impose different procurement cycles, compliance requirements, and service expectations that shape commercial engagement. Finally, distribution channel segmentation-direct distribution, hospital pharmacies, online pharmacies, and retail pharmacies-illustrates how route-to-market choices influence pricing, promotional focus, and product support investments, underscoring the need for channel-specific value propositions and partnership models.

Regional regulatory, clinical practice, and distribution nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access and commercialization strategies

Regional dynamics vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory frameworks, clinical practice patterns, and supply chain architectures that influence product access and commercialization. In the Americas, practice consolidation among clinics and increasing use of digital procurement create efficiencies but also raise expectations for bundled service offerings and training support; regulatory pathways tend to favor well-established pharmacovigilance systems, which informs post-market surveillance strategies.

Across Europe, the Middle East & Africa, regulatory heterogeneity and divergent reimbursement models require tailored regulatory and market access approaches, while growing investments in veterinary education and welfare standards are driving demand for evidence-based analgesic protocols. The Asia-Pacific region exhibits rapid infrastructure development, expanding veterinary service networks, and variable local manufacturing capacity, which together incentivize partnerships with regional distributors and investments in localized supply chain resilience. Navigating these regional nuances calls for adaptive regulatory strategy, culturally attuned marketing, and distribution models that reconcile global product standards with local market realities.

Competitive dynamics and strategic behaviours among pharmaceutical and specialty animal health companies shaping differentiation through evidence, services, and channel focus

The competitive landscape in veterinary pain management is characterized by a mix of established pharmaceutical manufacturers, specialty animal health companies, and agile innovators developing new formulations and delivery systems. Leading organizations prioritize robust clinical evidence generation, targeted educational outreach to veterinary professionals, and investments in product safety monitoring to differentiate their offerings. Strategic collaborations and licensing agreements are common as companies seek complementary capabilities in formulation science, distribution networks, or regional regulatory expertise.

Product differentiation increasingly depends on demonstrating superior tolerability, simplified dosing regimens, or clear advantages in real-world settings, while companies that offer integrated support services-such as training modules, dosing calculators, and client education materials-achieve deeper clinical engagement. Competitive positioning also reflects decisions about channel focus; some companies emphasize partnerships with hospital pharmacies and veterinary hospitals for high-touch engagement, whereas others optimize for retail and online pharmacy distribution to capture convenience-driven end users. These dynamics create openings for specialized entrants to capture niche segments while larger firms consolidate presence through portfolio breadth and service depth.

Actionable strategic measures for manufacturers and distributors to fortify supply resilience, accelerate clinician adoption, and optimize channel-specific commercial approaches

Industry leaders should pursue a set of pragmatic actions that strengthen resilience, accelerate adoption of differentiated therapies, and align commercial models with evolving clinical practice. First, manufacturers and distributors need to execute comprehensive supply chain mapping and dual-sourcing strategies to reduce exposure to tariff-driven disruptions and raw material shortages. Second, investing in multimodal analgesia education for veterinary professionals and clients will support evidence-based prescribing and enhance product value through demonstrable outcomes and adherence improvements.

Third, prioritizing development of user-centric administration formats-such as long-acting injectables or transdermal patches-can address adherence challenges and improve patient welfare across species. Fourth, companies must tailor channel strategies to meet the distinct needs of veterinary clinics, hospitals, retail pharmacies, and online platforms, offering differentiated commercial incentives and service bundles. Finally, proactive regulatory engagement and robust post-market surveillance will mitigate safety concerns and support faster market acceptance; collectively, these measures will enable organizations to respond to competitive pressures while delivering measurable benefits to clinicians and animal owners.

Rigorous mixed-method research approach combining expert interviews, clinical literature synthesis, and scenario-based supply chain analysis to produce actionable insights

The research methodology underpinning this analysis integrates qualitative expert interviews, systematic literature review, and synthesis of regulatory guidance and clinical practice resources to ensure balanced perspectives across stakeholders. Primary inputs included structured consultations with practicing veterinarians, pharmacologists, regulatory specialists, and distribution executives to capture real-world decision drivers, therapeutic preferences, and procurement practices. Secondary inputs relied on peer-reviewed clinical studies, pharmacology texts, and public regulatory documentation to validate safety profiles, administration considerations, and labeling implications for key analgesic agents and delivery platforms.

Analytical approaches combined cross-segmentation mapping with scenario-based supply chain stress testing to evaluate vulnerabilities and response options. Triangulation between primary interviews and secondary sources was applied to reduce bias and enhance the robustness of thematic conclusions. Where appropriate, sensitivity analyses were used to examine the implications of tariff-induced cost pressures, channel shifts, and adoption of new administration modalities. This mixed-method framework supports actionable insights while preserving methodological transparency and reproducibility.

Synthesis of strategic priorities that reconcile clinical innovation, regulatory expectations, and commercial resilience to advance veterinary pain care and organizational performance

In conclusion, the veterinary pain management sector is at an inflection point where clinical innovation, distribution evolution, and macroeconomic pressures converge to redefine opportunity and risk. Stakeholders that proactively integrate supply chain resilience, invest in clinician education, and tailor product and channel strategies to species- and setting-specific needs will be best positioned to deliver improved patient outcomes and secure commercial advantage. The interplay between regulatory expectations, administration route preferences, and end-user procurement behaviors demands coordinated strategies that align clinical evidence with pragmatic go-to-market tactics.

As markets continue to evolve, organizations should prioritize adaptive planning, collaborative partnerships, and sustained investment in post-market evidence generation to support long-term acceptance and trust. By focusing on these strategic pillars, companies and care providers can navigate near-term disruptions while advancing toward higher standards of pain management across companion, equine, and livestock populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pain Management Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs
  • 8.3. Equine
  • 8.4. Livestock

9. Veterinary Pain Management Market, by Product Type

  • 9.1. Local Anesthetics
  • 9.2. Nonsteroidal Anti-Inflammatory Drugs
    • 9.2.1. Carprofen
    • 9.2.2. Flunixin
    • 9.2.3. Meloxicam
    • 9.2.4. Robenacoxib
  • 9.3. Opioids

10. Veterinary Pain Management Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral
  • 10.3. Topical
    • 10.3.1. Gels
    • 10.3.2. Patches
    • 10.3.3. Sprays
  • 10.4. Transdermal

11. Veterinary Pain Management Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Research Institutes
  • 11.3. Retail Pharmacies
  • 11.4. Veterinary Clinics
  • 11.5. Veterinary Hospitals

12. Veterinary Pain Management Market, by Distribution Channel

  • 12.1. Direct Distribution
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Veterinary Pain Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Pain Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Pain Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Pain Management Market

17. China Veterinary Pain Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Boehringer Ingelheim International GmbH
  • 18.6. Ceva Sante Animale S.A.
  • 18.7. Dechra Pharmaceuticals PLC
  • 18.8. Elanco Animal Health Incorporated
  • 18.9. Merck & Co., Inc.
  • 18.10. Norbrook Laboratories Limited
  • 18.11. Phibro Animal Health Corporation
  • 18.12. Vetoquinol S.A.
  • 18.13. Virbac S.A.
  • 18.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)